{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:52:08Z","timestamp":1761709928587,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12DK094721","P30DK036836"],"award-info":[{"award-number":["K12DK094721","P30DK036836"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1053\/j.ackd.2021.05.001","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T20:51:44Z","timestamp":1639601504000},"page":"309-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sodium-Glucose Transporter Inhibition in Adult and Pediatric Patients with Type 1 Diabetes Mellitus"],"prefix":"10.1053","volume":"28","author":[{"given":"Rebecca J.","family":"Vitale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori M.","family":"Laffel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ackd.2021.05.001_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tips.2010.11.011","article-title":"Renal glucose reabsorption inhibitors to treat diabetes","volume":"32","author":"Bailey","year":"2011","journal-title":"Trends Pharmacol Sci"},{"issue":"Supplement_1","key":"10.1053\/j.ackd.2021.05.001_bib2","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/ndt\/gfz230","article-title":"Renal physiology of glucose handling and therapeutic implications","volume":"35","author":"Cherney","year":"2020","journal-title":"Nephrol Dial Transpl"},{"issue":"Supplement_1","key":"10.1053\/j.ackd.2021.05.001_bib3","doi-asserted-by":"crossref","first-page":"i24","DOI":"10.1093\/ndt\/gfz228","article-title":"Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes","volume":"35","author":"van Raalte","year":"2020","journal-title":"Nephrol Dial Transpl"},{"issue":"24","key":"10.1053\/j.ackd.2021.05.001_bib4","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.ackd.2021.05.001_bib5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.ackd.2021.05.001_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2021.05.001_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2021.05.001_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.ackd.2021.05.001_bib9","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2021.05.001_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.diabres.2016.09.024","article-title":"Type 1 diabetes in older adults: comparing treatments and chronic complications in the United States T1D Exchange and the German\/Austrian DPV registries","volume":"122","author":"Weinstock","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1053\/j.ackd.2021.05.001_bib11","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc15-2322","article-title":"Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-on","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ackd.2021.05.001_bib12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey Kenneth","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.ackd.2021.05.001_bib13","doi-asserted-by":"crossref","first-page":"108462","DOI":"10.1016\/j.diabres.2020.108462","article-title":"The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes","volume":"170","author":"Gillard","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"10.1053\/j.ackd.2021.05.001_bib14","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.2337\/dc17-0403","article-title":"Use of adjuvant pharmacotherapy in type 1 diabetes: international comparison of 49,996 individuals in the prospective diabetes follow-up and T1D exchange registries","volume":"40","author":"Lyons","year":"2017","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ackd.2021.05.001_bib15","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1053\/j.ackd.2021.05.001_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11892-016-0721-y","article-title":"Stress hyperglycemia during surgery and anesthesia: pathogenesis and clinical implications","volume":"16","author":"Palermo","year":"2016","journal-title":"Curr Diab Rep"},{"key":"10.1053\/j.ackd.2021.05.001_bib17","first-page":"8769714","article-title":"Euglycemic diabetic ketoacidosis in pregnancy: a case report and review of current literature","volume":"2019","author":"Jaber","year":"2019","journal-title":"Case Rep Crit Care"},{"issue":"5866","key":"10.1053\/j.ackd.2021.05.001_bib18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/bmj.2.5866.578","article-title":"Euglycaemic diabetic ketoacidosis","volume":"2","author":"Munro","year":"1973","journal-title":"Br Med J"},{"issue":"11","key":"10.1053\/j.ackd.2021.05.001_bib19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1089\/dia.2017.0267","article-title":"Altered patterns of early metabolic decompensation in type 1 diabetes during treatment with a SGLT2 inhibitor: an insulin pump suspension study","volume":"19","author":"Patel","year":"2017","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"10.1053\/j.ackd.2021.05.001_bib20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ackd.2021.05.001_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/dia.2018.0246","article-title":"Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"10.1053\/j.ackd.2021.05.001_bib22","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/dom.13811","article-title":"Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: the STOP DKA Protocol","volume":"21","author":"Goldenberg","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1053\/j.ackd.2021.05.001_bib23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/1060028019859323","article-title":"Sodium-glucose cotransporters as potential therapeutic targets in patients with type 1 diabetes mellitus: an update on phase 3 clinical trial data","volume":"53","author":"Patel","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"Suppl 2","key":"10.1053\/j.ackd.2021.05.001_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/dom.13749","article-title":"Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: a review of randomized controlled trials","volume":"21","author":"Boeder","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1053\/j.ackd.2021.05.001_bib25","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/dom.13807","article-title":"Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: a randomized, double-blind, phase 3 trial","volume":"21","author":"Kaku","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1053\/j.ackd.2021.05.001_bib26","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1053\/j.ackd.2021.05.001_bib27","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ackd.2021.05.001_bib28","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ackd.2021.05.001_bib29","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1053\/j.ackd.2021.05.001_bib30","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ackd.2021.05.001_bib31","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ackd.2021.05.001_bib32","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1053\/j.ackd.2021.05.001_bib33","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1053\/j.ackd.2021.05.001_bib34","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/jdi.13181","article-title":"Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: an uncontrolled, open-label extension of a phase III study","volume":"11","author":"Kaku","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"10","key":"10.1053\/j.ackd.2021.05.001_bib35","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2337\/dc19-0937","article-title":"The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes","volume":"42","author":"van Raalte","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1053\/j.ackd.2021.05.001_bib36","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1515\/jpem-2019-0389","article-title":"Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report","volume":"33","author":"Candler","year":"2020","journal-title":"J Pediatr Endocrinol Metab JPEM"},{"issue":"4","key":"10.1053\/j.ackd.2021.05.001_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/17446651.2018.1499467","article-title":"The present and future treatment of pediatric type 2 diabetes","volume":"13","author":"Van Name","year":"2018","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"7","key":"10.1053\/j.ackd.2021.05.001_bib38","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in children and adolescents with type 2 diabetes","volume":"381","author":"Tamborlane","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2021.05.001_bib39","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/pedi.12626","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes","volume":"19","author":"Tamborlane","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"8","key":"10.1053\/j.ackd.2021.05.001_bib40","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/dme.13629","article-title":"Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial","volume":"35","author":"Laffel","year":"2018","journal-title":"Diabet Med"},{"issue":"11","key":"10.1053\/j.ackd.2021.05.001_bib41","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/dom.12975","article-title":"Effects of dapagliflozin on insulin-requirement, glucose excretion and \u00df-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes","volume":"19","author":"Biester","year":"2017","journal-title":"Diabetes Obes Metab"},{"author":"Francisco","key":"10.1053\/j.ackd.2021.05.001_bib44"},{"author":"Buckingham","key":"10.1053\/j.ackd.2021.05.001_bib45"},{"issue":"9","key":"10.1053\/j.ackd.2021.05.001_bib50","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.2337\/dc19-0548","article-title":"Exploring patient preferences for adjunct-to-insulin therapy in type 1 diabetes","volume":"42","author":"Perkins","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1053\/j.ackd.2021.05.001_bib51","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2337\/dci19-0008","article-title":"SGLT inhibitors for type 1 diabetes: proceed with extreme caution","volume":"42","author":"Wolfsdorf","year":"2019","journal-title":"Diabetes Care"},{"author":"Mahmud","key":"10.1053\/j.ackd.2021.05.001_bib52"},{"key":"10.1053\/j.ackd.2021.05.001_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2042018820938545","article-title":"SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects","volume":"11","author":"Janssens","year":"2020","journal-title":"Ther Adv Endocrinol Metab"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:03:24Z","timestamp":1761548604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559521000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1548559521000379"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2021.05.001","relation":{},"ISSN":["1548-5595"],"issn-type":[{"type":"print","value":"1548-5595"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Transporter Inhibition in Adult and Pediatric Patients with Type 1 Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2021.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}